A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 639, 2020 Jul 13.
Article
em En
| MEDLINE
| ID: mdl-32660611
Palavras-chave
COVID-19; Ultomiris; acute pneumonia; acute respiratory distress syndrome; adult; antibodies; complement; complement inhibitor; hospitalization; humanized; lung injury; monoclonal; randomized controlled study; ravulizumab; respiratory distress syndrome; severe acute respiratory distress syndrome coronavirus 2; severe acute respiratory syndrome; severe pneumonia; viral
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Pneumonia Viral
/
Infecções por Coronavirus
/
Inativadores do Complemento
/
Anticorpos Monoclonais Humanizados
/
Betacoronavirus
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Guideline
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Trials
Assunto da revista:
MEDICINA
/
TERAPEUTICA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos